Abstract
Background and Aim: The present study aimed to evaluate the anxiety, depression, and fear in people with and without diabetes during the transmission of the SARS-CoV-2 Omicron variant.
Methods: In this comparative study (n= 353), people with diabetes (n= 121) and those without diabetes (n= 232) were investigated for physiological aspects of COVID-19 during the SARS-CoV-2 Omicron variant outbreak. This study was performed at the Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia. On request, the participants responded to the survey questionnaires, providing data on demographics, Generalized Anxiety Disorder (GAD-7), and Patient Health Questionnaire-2 (PHQ-2) to screen for anxiety, depression, and COVID-19-related fears.
Results: The GAD statement revealed a significantly higher degree of nervousness and anxiety among people with diabetes when compared to people without diabetes (P = 0.001). For the other GAD statements, no statistical difference was observed between the responses of people with and without diabetes, including the overall GAD-7 (P = 0.091). The PHQ-2 statement, concerning a feeling of depression or hopelessness noted a significant escalation among diabetes compared to nondiabetes (P = 0.004). Furthermore, in the overall PHQ-2, a significant escalation (P = 0.011) was noticed among people with diabetes compared to nondiabetes. In addition, people with diabetes had a significantly high (P = 0.037) COVID-19-related fear reported, compared to people without diabetes.
Conclusion: The need for comprehensive research is urgent, as it will facilitate a better understanding of the physiological aspects of COVID-19 for patients with diabetes.
Keywords: Diabetes, Omicron, COVID-19, SARS-CoV-2, Depression, Anxiety, Saudi Arabia
[1]
Ma W, Yang J, Fu H, et al. Genomic perspectives on the emerging SARS-CoV-2 omicron variant. Genom Proteom Bioinf 2022; S1672-0229(22):2
[http://dx.doi.org/10.1016/j.gpb.2022.01.001]
[http://dx.doi.org/10.1016/j.gpb.2022.01.001]
[2]
He X, Hong W, Pan X, Lu G, Wei X. SARS‐CoV‐2 Omicron variant: Characteristics and prevention. MedComm 2021; 2(4): 838-45.
[http://dx.doi.org/10.1002/mco2.110] [PMID: 34957469]
[http://dx.doi.org/10.1002/mco2.110] [PMID: 34957469]
[3]
Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci 2021; 25(24): 8012-8.
[PMID: 34982465]
[PMID: 34982465]
[4]
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323(14): 1406-7.
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[5]
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020; 318(5): E736-41.
[http://dx.doi.org/10.1152/ajpendo.00124.2020] [PMID: 32228322]
[http://dx.doi.org/10.1152/ajpendo.00124.2020] [PMID: 32228322]
[6]
Al Dawish MA, Robert AA. COVID-19 in people with diabetes: Epidemiological perspectives and public health actions in the Middle East and North Africa (MENA) region. Curr Diabetes Rev 2021; 17(5): e211020187087.
[http://dx.doi.org/10.2174/1573399816666201021154839] [PMID: 33087031]
[http://dx.doi.org/10.2174/1573399816666201021154839] [PMID: 33087031]
[7]
Robert AA, Al Dawish MA. COVID-19 in people with diabetes: Perspectives from Saudi Arabia. Curr Diabetes Rev 2021; 17(6): e111020187810.
[http://dx.doi.org/10.2174/1573399816999201110195222] [PMID: 33176657]
[http://dx.doi.org/10.2174/1573399816999201110195222] [PMID: 33176657]
[8]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[9]
Wang C, Pan R, Wan X, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health 2020; 17(5): 1729.
[http://dx.doi.org/10.3390/ijerph17051729] [PMID: 32155789]
[http://dx.doi.org/10.3390/ijerph17051729] [PMID: 32155789]
[10]
Musche V, Kohler H, Bäuerle A, et al. COVID-19-related fear, risk perception, and safety behavior in individuals with diabetes. Healthcare (Basel) 2021; 9(4): 480.
[http://dx.doi.org/10.3390/healthcare9040480] [PMID: 33919519]
[http://dx.doi.org/10.3390/healthcare9040480] [PMID: 33919519]
[11]
Bäuerle A, Teufel M, Musche V, et al. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: A cross-sectional study in Germany. J Public Health (Oxf) 2020; 42(4): 672-8.
[http://dx.doi.org/10.1093/pubmed/fdaa106] [PMID: 32657323]
[http://dx.doi.org/10.1093/pubmed/fdaa106] [PMID: 32657323]
[13]
Robert AA, Al Saeed A, Al Dawish MA. COVID-19 among people with diabetes mellitus in Saudi Arabia: Current situation and new per-spectives. Diabetes Metab Syndr 2021; 15(5): 102231.
[http://dx.doi.org/10.1016/j.dsx.2021.102231] [PMID: 34330072]
[http://dx.doi.org/10.1016/j.dsx.2021.102231] [PMID: 34330072]
[14]
Saudi Arabia, UAE confirm first omicron COVID-19 cases. Available from: https://www.arabnews.com/node/1978791/saudi-arabia
[15]
Saudi Arabia reports 5,281 new COVID-19 cases, 2 deaths. Available from: https://www.arabnews.com/node/2004871/saudi-arabia
[16]
Robert AA, Al Dawish MA. The worrying trend of diabetes mellitus in Saudi Arabia: An urgent call to action. Curr Diabetes Rev 2020; 16(3): 204-10.
[http://dx.doi.org/10.2174/1573399815666190531093735] [PMID: 31146665]
[http://dx.doi.org/10.2174/1573399815666190531093735] [PMID: 31146665]
[17]
Abdulaziz Al Dawish M, Alwin Robert A, Braham R, et al. Diabetes mellitus in Saudi Arabia: A review of the recent literature. Curr Diabetes Rev 2016; 12(4): 359-68.
[http://dx.doi.org/10.2174/1573399811666150724095130] [PMID: 26206092]
[http://dx.doi.org/10.2174/1573399811666150724095130] [PMID: 26206092]
[18]
Robert A, Al Dawish M, Braham R, Musallam M, Al Hayek A, Al Kahtany N. Type 2 diabetes mellitus in Saudi Arabia: Major challenges and possible solutions. Curr Diabetes Rev 2016; 13(1): 59-64.
[http://dx.doi.org/10.2174/1573399812666160126142605] [PMID: 26813972]
[http://dx.doi.org/10.2174/1573399812666160126142605] [PMID: 26813972]
[19]
Johnson SU, Ulvenes PG, Øktedalen T, Hoffart A. Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol 2019; 10: 1713.
[http://dx.doi.org/10.3389/fpsyg.2019.01713] [PMID: 31447721]
[http://dx.doi.org/10.3389/fpsyg.2019.01713] [PMID: 31447721]
[20]
Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46(3): 266-74.
[http://dx.doi.org/10.1097/MLR.0b013e318160d093] [PMID: 18388841]
[http://dx.doi.org/10.1097/MLR.0b013e318160d093] [PMID: 18388841]
[21]
Löwe B, Kroenke K, Gräfe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res 2005; 58(2): 163-71.
[http://dx.doi.org/10.1016/j.jpsychores.2004.09.006] [PMID: 15820844]
[http://dx.doi.org/10.1016/j.jpsychores.2004.09.006] [PMID: 15820844]
[22]
Thakur V, Ratho RK. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol 2022; 94(5): 1821-4.
[http://dx.doi.org/10.1002/jmv.27541] [PMID: 34936120]
[http://dx.doi.org/10.1002/jmv.27541] [PMID: 34936120]
[23]
Moradian S, Teufel M, Jahre L, et al. Mental health burden of patients with diabetes before and after the initial outbreak of COVID-19: Predictors of mental health impairment. BMC Public Health 2021; 21(1): 2068.
[http://dx.doi.org/10.1186/s12889-021-12101-z] [PMID: 34763688]
[http://dx.doi.org/10.1186/s12889-021-12101-z] [PMID: 34763688]
[24]
Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: A systematic review and meta-analysis. Diabetologia 2010; 53(12): 2480-6.
[http://dx.doi.org/10.1007/s00125-010-1874-x] [PMID: 20711716]
[http://dx.doi.org/10.1007/s00125-010-1874-x] [PMID: 20711716]
[25]
Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of comorbid depression in adults with type 2 diabetes: A systematic review and meta-analysis. Diabet Med 2006; 23(11): 1165-73.
[http://dx.doi.org/10.1111/j.1464-5491.2006.01943.x] [PMID: 17054590]
[http://dx.doi.org/10.1111/j.1464-5491.2006.01943.x] [PMID: 17054590]
[26]
Kohler H, Bäuerle A, Schweda A, et al. Increased COVID-19-related fear and subjective risk perception regarding COVID-19 affects behavior in individuals with internal high-risk diseases. J Prim Care Community Health 2021; 12: 2150132721996898.
[http://dx.doi.org/10.1177/2150132721996898] [PMID: 33719697]
[http://dx.doi.org/10.1177/2150132721996898] [PMID: 33719697]
[27]
Bäuerle A, Musche V, Schmidt K, et al. Mental health burden of German cancer patients before and after the outbreak of COVID-19: Predictors of mental health impairment. Int J Environ Res Public Health 2021; 18(5): 2318.
[http://dx.doi.org/10.3390/ijerph18052318] [PMID: 33652949]
[http://dx.doi.org/10.3390/ijerph18052318] [PMID: 33652949]
[28]
Chao AM, Wadden TA, Clark JM, et al. Changes in the prevalence of symptoms of depression, loneliness, and insomnia in U.S. older adults with type 2 diabetes during the COVID-19 pandemic: The look AHEAD study. Diabetes Care 2022; 45(1): 74-82.
[http://dx.doi.org/10.2337/dc21-1179] [PMID: 34753805]
[http://dx.doi.org/10.2337/dc21-1179] [PMID: 34753805]
[29]
Brody DJ, Pratt LA, Hughes JP. Prevalence of depression among adults aged 20 and over: United States, 2013-2016. NCHS Data Brief 2018; (303): 1-8.
[PMID: 29638213]
[PMID: 29638213]
[30]
Wang Y, Lopez JMS, Bolge SC, Zhu VJ, Stang PE. Depression among people with type 2 diabetes mellitus, US National Health and Nutrition Examination Survey (NHANES), 2005-2012. BMC Psychiatry 2016; 16(1): 88.
[http://dx.doi.org/10.1186/s12888-016-0800-2] [PMID: 27044315]
[http://dx.doi.org/10.1186/s12888-016-0800-2] [PMID: 27044315]
[31]
Myers BA, Klingensmith R, de Groot M. Emotional correlates of the COVID-19 pandemic in individuals with and without diabetes. Diabetes Care 2022; 45(1): 42-58.
[http://dx.doi.org/10.2337/dc21-0769] [PMID: 34740911]
[http://dx.doi.org/10.2337/dc21-0769] [PMID: 34740911]
[32]
Al-Sofiani ME, Albunyan S, Alguwaihes AM, Kalyani RR, Golden SH, Alfadda A. Determinants of mental health outcomes among people with and without diabetes during the COVID ‐19 outbreak in the Arab Gulf Region. J Diabetes 2021; 13(4): 339-52.
[http://dx.doi.org/10.1111/1753-0407.13149] [PMID: 33351239]
[http://dx.doi.org/10.1111/1753-0407.13149] [PMID: 33351239]
[33]
Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 severity is tripled in the diabetes community: A prospective analysis of the Pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care 2021; 44(2): 526-32.
[http://dx.doi.org/10.2337/dc20-2260] [PMID: 33268335]
[http://dx.doi.org/10.2337/dc20-2260] [PMID: 33268335]
[34]
Al-Rahimi JS, Nass NM, Hassoubah SA, Wazqar DY, Alamoudi SA. Levels and predictors of fear and health anxiety during the current outbreak of COVID-19 in immunocompromised and chronic disease patients in Saudi Arabia: A cross-sectional correlational study. PLoS One 2021; 16(4): e0250554.
[http://dx.doi.org/10.1371/journal.pone.0250554] [PMID: 33901260]
[http://dx.doi.org/10.1371/journal.pone.0250554] [PMID: 33901260]
